ProShare Advisors
ADMA icon

ProShare Advisors’s ADMA Biologics ADMA Stock Holding History

ProShare Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$339K Sell
40,518
-6,276
-13% -$57.2K ﹤0.01% 1343
2026
Q1 		$422K Sell
46,794
-8,861
-16% -$140K ﹤0.01% 1157
2025
Q4 		$1.02M Buy
55,655
+3,362
+6% +$56.7K ﹤0.01% 814
2025
Q3 		$767K Sell
52,293
-8,496
-14% -$146K ﹤0.01% 903
2025
Q2 		$1.11M Sell
60,789
-4,092
-6% -$83.4K ﹤0.01% 785
2025
Q1 		$1.29M Sell
64,881
-14,405
-18% -$249K ﹤0.01% 751
2024
Q4 		$1.36M Buy
79,286
+18,375
+30% +$346K ﹤0.01% 801
2024
Q3 		$1.22M Buy
60,911
+18,048
+42% +$281K ﹤0.01% 763
2024
Q2 		$479K Sell
42,863
-11,430
-21% -$95.9K ﹤0.01% 1003
2024
Q1 		$358K Buy
54,293
+4,570
+9% +$25K ﹤0.01% 1301
2023
Q4 		$225K Buy
49,723
+7,655
+18% +$28.3K ﹤0.01% 1574
2023
Q3 		$151K Buy
42,068
+290
+0.7% +$1.12K ﹤0.01% 1549
2023
Q2 		$154K Buy
41,778
+1,821
+5% +$6.75K ﹤0.01% 1602
2023
Q1 		$132K Sell
39,957
-231
-0.6% -$799 ﹤0.01% 1537
2022
Q4 		$156K Buy
40,188
+3,184
+9% +$9.82K ﹤0.01% 1555
2022
Q3 		$90K Buy
37,004
+834
+2% +$2K ﹤0.01% 1581
2022
Q2 		$71K Buy
36,170
+15,905
+78% +$31.3K ﹤0.01% 1660
2022
Q1 		$37K Sell
20,265
-7,311
-27% -$11.4K ﹤0.01% 2133
2021
Q4 		$39K Buy
+27,576
New +$36.2K ﹤0.01% 2309
2021
Q2 		– Sell
-17,612
Closed -$31K – 2369
2021
Q1 		$31K Buy
17,612
+3,009
+21% +$6.89K ﹤0.01% 2252
2020
Q4 		$28K Sell
14,603
-6,689
-31% -$14.1K ﹤0.01% 2079
2020
Q3 		$51K Sell
21,292
-686
-3% -$1.88K ﹤0.01% 1591
2020
Q2 		$64K Buy
21,978
+9,905
+82% +$28.5K ﹤0.01% 1616
2020
Q1 		$35K Sell
12,073
-7,579
-39% -$26.2K ﹤0.01% 1128
2019
Q4 		$79K Buy
+19,652
New +$85.7K ﹤0.01% 1715

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

ProShare Advisors's ADMA Position: Q2 2026 in Review

ProShare Advisors reduced its ADMA Biologics (ADMA) stake by 13% in Q2 2026, selling an estimated $57.2K and leaving 40,518 shares worth $339K. The position accounts for ﹤0.01% of the portfolio, ranked #1343.

ProShare Advisors first reported a position in ADMA in Q4 2019 and has held it in 25 quarters since. The position peaked at $1.36M in Q4 2024. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • ProShare Advisors held 40,518 shares of ADMA Biologics worth $339K as of Q2 2026.
  • ProShare Advisors sold 6,276 ADMA Biologics shares in Q2 2026, an estimated $57.2K.
  • ADMA Biologics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1343 holding.
  • ProShare Advisors first reported a position in ADMA Biologics in Q4 2019 and has held it in 25 quarters since.
  • ProShare Advisors's ADMA Biologics position peaked at $1.36M in Q4 2024.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.